Catecholamines in Alzheimer's Disease: A Systematic Review and Meta-Analysis

Xiongfeng Pan, Atipatsa C. Kaminga, Peng Jia, Shi Wu Wen, Kwabena Acheampong, Aizhong Liu*

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

17 Citations (Scopus)
57 Downloads (Pure)


Background and Purpose: Previous studies found inconsistent results regarding the relationship between Alzheimer's disease (AD) and catecholamines, such as dopamine (DA), norepinephrine (NE), and epinephrine (EPI). Therefore, the purpose of this study was to perform a systematic review and meta-analysis to evaluate the results of previous studies on this relationship.

Method: Literature retrieval of eligible studies was performed in four databases (Web of Science, PubMed, Embase, and PsycARTICLES). Standardized mean differences (SMDs) were calculated to assess differences in catecholamine concentrations between the AD groups and controls.

Results: Thirteen studies met the eligibility criteria. Compared with the controls, significant lower concentrations of NE (SMD = −1.10, 95% CI: −2.01 to −0.18, p = 0.019) and DA (SMD = −1.12, 95% CI: −1.88 to −0.37, p = 0.003) were observed in patients with AD. No difference was found in the concentrations of EPI between the two groups (SMD = −0.74, 95% CI: −1.85 to 0.37, p = 0.189).

Conclusion: Overall, these findings are in line with the hypothesis that reduced NE and DA may be an important indicator for AD (Registration number CRD42018112816).
Original languageEnglish
Article number184
Pages (from-to)1-12
Number of pages12
JournalFrontiers in Aging Neuroscience
Publication statusPublished - 11 Sep 2020




Dive into the research topics of 'Catecholamines in Alzheimer's Disease: A Systematic Review and Meta-Analysis'. Together they form a unique fingerprint.

Cite this